{"id":"rsv-f-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine uses a recombinant RSV fusion protein formulated with Novavax's Matrix-M adjuvant to elicit both humoral and cell-mediated immune responses. By targeting the F protein, a key surface antigen of RSV, the vaccine aims to prevent viral attachment and entry into respiratory epithelial cells, thereby reducing infection risk and disease severity.","oneSentence":"RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:40.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years)"},{"name":"Prevention of RSV disease in infants (via maternal immunization)"}]},"trialDetails":[{"nctId":"NCT06551506","phase":"PHASE4","title":"The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-19","conditions":"Respiratory Syncytial Virus Infection","enrollment":181},{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT07445763","phase":"","title":"TARSILA Real-World Evidence Study","status":"NOT_YET_RECRUITING","sponsor":"Inova Medical","startDate":"2026-04-30","conditions":"Respiratory Syncytial Virus (RSV), Maternal Immunization, Acute Respiratory Illness (ARI)","enrollment":5000},{"nctId":"NCT06593587","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-10-07","conditions":"Respiratory Syncytial Virus","enrollment":378},{"nctId":"NCT05035212","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Lower Respiratory Tract Illness","enrollment":38861},{"nctId":"NCT07185399","phase":"PHASE4","title":"Systems Biological Analysis of Immune Responses to RSV Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2025-10-13","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":14},{"nctId":"NCT07296120","phase":"PHASE4","title":"RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients","status":"NOT_YET_RECRUITING","sponsor":"The Cooper Health System","startDate":"2026-01-01","conditions":"CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic","enrollment":30},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT06684743","phase":"PHASE4","title":"Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults","status":"RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2024-11-18","conditions":"RSV","enrollment":690000},{"nctId":"NCT07122661","phase":"","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease","enrollment":1},{"nctId":"NCT07232706","phase":"PHASE3","title":"Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2026-01","conditions":"RSV Immunization","enrollment":1000},{"nctId":"NCT04908683","phase":"PHASE3","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-07-21","conditions":"Respiratory Syncytial Viruses, Lower Respiratory Tract Disease","enrollment":25236},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT06077149","phase":"PHASE4","title":"Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2023-11-07","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":152},{"nctId":"NCT06647654","phase":"","title":"Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Respiratory Syncytial Virus, Respiratory Tract Diseases","enrollment":1},{"nctId":"NCT06556147","phase":"PHASE1","title":"A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2024-08-13","conditions":"Healthy Volunteers","enrollment":144},{"nctId":"NCT06473519","phase":"PHASE3","title":"A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":453},{"nctId":"NCT06573281","phase":"PHASE1","title":"A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-30","conditions":"Respiratory Syncytial Virus Infections","enrollment":213},{"nctId":"NCT05842967","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-11","conditions":"RESPIRATORY SYNCYTIAL VIRUS (RSV)","enrollment":885},{"nctId":"NCT06325657","phase":"PHASE3","title":"A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-12","conditions":"Respiratory Syncytial Virus","enrollment":648},{"nctId":"NCT07041190","phase":"PHASE3","title":"Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.","status":"NOT_YET_RECRUITING","sponsor":"PENTA Foundation","startDate":"2025-09","conditions":"RSV Immunization","enrollment":1500},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":"Respiratory Syncytial Virus Vaccination","enrollment":160},{"nctId":"NCT05083585","phase":"PHASE3","title":"A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-10-08","conditions":"Respiratory Syncytial Virus Prevention","enrollment":250},{"nctId":"NCT05242432","phase":"PHASE3","title":"A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus Prevention","enrollment":2192},{"nctId":"NCT06955728","phase":"PHASE4","title":"A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.","status":"NOT_YET_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2025-05-01","conditions":"RSV Infections, RSV Immunisation, Preterm Labour","enrollment":13000},{"nctId":"NCT02624947","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization","status":"COMPLETED","sponsor":"Novavax","startDate":"2015-12","conditions":"Respiratory Syncytial Virus Infections","enrollment":4636},{"nctId":"NCT06890429","phase":"PHASE2","title":"Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-07","conditions":"Respiratory Synctial Virus Infections","enrollment":120},{"nctId":"NCT05900154","phase":"PHASE1","title":"A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-22","conditions":"RESPIRATORY SYNCYTIAL VIRUS (RSV)","enrollment":128},{"nctId":"NCT06754605","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-06","conditions":"Respiratory Syncytial Virus","enrollment":480},{"nctId":"NCT04424316","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Respiratory Tract Infection","enrollment":14727},{"nctId":"NCT03606512","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-01-21","conditions":"Respiratory Syncytial Virus","enrollment":38},{"nctId":"NCT03339713","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-12-07","conditions":"Healthy","enrollment":180},{"nctId":"NCT04354480","phase":"PHASE1","title":"A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-05-15","conditions":"Healthy","enrollment":36},{"nctId":"NCT05788237","phase":"PHASE1","title":"A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-09","conditions":"Healthy","enrollment":508},{"nctId":"NCT04528719","phase":"PHASE1","title":"A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-09-30","conditions":"Respiratory Syncytial Virus","enrollment":651},{"nctId":"NCT05970744","phase":"PHASE1","title":"Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Respiratory Syncytial Virus Infections","enrollment":60},{"nctId":"NCT05281263","phase":"PHASE1","title":"Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults","status":"COMPLETED","sponsor":"Blue Lake Biotechnology Inc.","startDate":"2022-07-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":30},{"nctId":"NCT05301322","phase":"PHASE3","title":"Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-13","conditions":"Respiratory Syncytial Virus","enrollment":1471},{"nctId":"NCT05096208","phase":"PHASE3","title":"Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-21","conditions":"RSV","enrollment":1028},{"nctId":"NCT02608502","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2015-11","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":11850},{"nctId":"NCT02266628","phase":"PHASE2","title":"Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":1599},{"nctId":"NCT02593071","phase":"PHASE2","title":"Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.","status":"COMPLETED","sponsor":"Novavax","startDate":"2015-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":1330},{"nctId":"NCT02247726","phase":"PHASE2","title":"RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":50},{"nctId":"NCT04519073","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus","status":"COMPLETED","sponsor":"Virometix","startDate":"2020-09-07","conditions":"Acute Bronchiolitis Due to Respiratory Syncytial Virus","enrollment":60},{"nctId":"NCT03026348","phase":"PHASE2","title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-01","conditions":"Respiratory Syncytial Viruses","enrollment":300},{"nctId":"NCT02927873","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":107},{"nctId":"NCT03049488","phase":"PHASE1","title":"Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-02-22","conditions":"Respiratory Syncytial Virus","enrollment":95},{"nctId":"NCT02472548","phase":"PHASE1","title":"A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine","status":"COMPLETED","sponsor":"Dalhousie University","startDate":"2015-05","conditions":"Respiratory Syncytial Virus","enrollment":40},{"nctId":"NCT03795441","phase":"PHASE1","title":"A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-01-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT03473002","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-16","conditions":"Antiviral Prophylaxis, Respiratory Syncytial Virus Infection","enrollment":21},{"nctId":"NCT02830932","phase":"PHASE1","title":"Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-06-22","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":66},{"nctId":"NCT02298179","phase":"PHASE1","title":"A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-19","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":288},{"nctId":"NCT02958540","phase":"PHASE1","title":"Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine","status":"UNKNOWN","sponsor":"Mucosis BV","startDate":"2016-10","conditions":"Respiratory Syncytial Viral Infections","enrollment":48},{"nctId":"NCT01905215","phase":"PHASE1","title":"Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-22","conditions":"Infections, Respiratory Syncytial Virus","enrollment":128},{"nctId":"NCT01960686","phase":"PHASE2","title":"RSV F Dose-Ranging Study in Women","status":"COMPLETED","sponsor":"Novavax","startDate":"2013-10","conditions":"Respiratory Syncytial Virus Infections","enrollment":720},{"nctId":"NCT02296463","phase":"PHASE1","title":"A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-11","conditions":"Respiratory Synctial Virus","enrollment":32},{"nctId":"NCT01805921","phase":"PHASE1","title":"RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.","status":"COMPLETED","sponsor":"ReiThera Srl","startDate":"2013-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":72},{"nctId":"NCT01704365","phase":"PHASE2","title":"RSV-F Vaccine Dose Ranging Study in Young Women","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":330},{"nctId":"NCT01709019","phase":"PHASE1","title":"RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":220},{"nctId":"NCT01290419","phase":"PHASE1","title":"Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2010-12","conditions":"Respiratory Syncytial Virus Infections","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RSV-F Vaccine","genericName":"RSV-F Vaccine","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection. Used for Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years), Prevention of RSV disease in infants (via maternal immunization).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}